GelStat Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GSAC research report →
Price Chart
About the company
GelStat Corporation operates as a consumer healthcare enterprise, specializing in the innovation, formulation, and commercialization of over-the-counter (OTC) and other non-prescription health solutions. Its diverse product portfolio addresses various common health concerns, featuring: GelStat Migraine, a patented remedy targeting migraine headache pain; Chews 2 Lose, an appetite-controlling gum designed to assist with weight management; All Natural Speed, formulated as an energy booster; and GelStat Sleep, intended to alleviate sleep disturbances and their related symptoms. GelStat distributes its solutions through a comprehensive network, reaching retailers, wholesalers, specialized distributors, and catalog merchandisers.
- CEO
- Javier G. Acosta
- IPO
- 1996
- Employees
- 2
- HQ
- Palm City, FL, US
Get TickerSpark's AI analysis on GSAC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $185.39K
- P/E
- -4.57
- PEG
- -0.02
- P/S
- 1.28
- P/B
- -0.78
- EV/EBITDA
- -7.55
- Div Yield
- 0.00%
- Gross Margin
- 88.25%
- Op Margin
- -104.30%
- Net Margin
- -141.98%
- ROE
- 17.09%
- ROIC
- 42.88%
Latest fiscal year · YoY change
- Revenue
- $267.96K-23.4%
- Gross Profit
- $-127,763-154.6%
- Op Income
- $-241,853
- Net Income
- $-326,575+12.4%
- EPS
- $0.00+100.0%
- OCF Growth
- -9.9%
- FCF Growth
- -9.9%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.64
- RSI (14)
- 56
- Avg Volume
- 128.75K
No earnings-call transcripts are available for GSAC yet.
- Free Float
- 85.8%
- Shares Outstanding
- 617.98M
- Float Shares
- 530.21M
of shares held by institutions
1 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 4, 22 | Goldfarb Adrian Graham | buy | 53,209,459 |
| Feb 4, 22 | Goldfarb Adrian Graham | buy | 9,843,750 |
| Feb 4, 22 | Goldfarb Adrian Graham | buy | 8,000,000 |
| Feb 4, 22 | Goldfarb Adrian Graham | buy | 16,000,000 |
| Dec 31, 12 | Goldfarb Adrian Graham | other | 2,052,600 |
| Mar 4, 15 | Goldfarb Adrian Graham | other | 719,600 |
| Nov 30, 20 | Goldfarb Adrian Graham | other | 280,400 |
| Feb 4, 22 | Acosta Javier G | other | 0 |
| May 3, 10 | Kieft Gerald N II | buy | 10,000 |
| Apr 30, 10 | Kieft Gerald N II | buy | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GSAC coverage
Recent articles, reports, and earnings notes.
No research on GSAC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GSAC report →GSAC Engineering Secures Multi-Year Recurring Revenue Contract
globenewswire.com · Jun 10
GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies Group
globenewswire.com · Sep 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.